Palisade Bio, Inc.

PALI

NASDAQHealthcareBiotechnology

在 GoAI 中打開

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

49/ 100

GoAI評分

Hold

Wait — insufficient conviction to act

估值

Fair Value

動能

Neutral

情緒

Bullish

風險韌性

High Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Palisade Bio, Inc. is a clinical-stage biopharmaceutical firm dedicated to identifying, advancing, and bringing to market orally administered treatments for significant conditions stemming from a compromised gastrointestinal mucosal barrier. The company's primary therapeutic candidate, LB1148, is an oral liquid formulation designed to inhibit digestive enzymes. Its goal is to safeguard gut integrity when the intestine experiences stress due to factors such as diminished blood supply, infections, or surgical procedures. Established in 2005, the company maintains its headquarters in Carlsbad, California.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: J. D. Finley
上市以來: 2007年3月30日
僱員: 14